Biosimilars Wedge Issue: Actavis Splits With GPhA In Supporting Calif. Notification Bill

05 Aug 2013
News

Brenda Sandburg @brendasandburg Brenda.Sandburg@informa.com

Executive Summary

PhRMA, BIO and Abbvie also back California bill that would require pharmacists to notify physicians of biosimilar substitution while GPhA, Boehringer Ingelheim and Novartis oppose it.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

Industries
BioPharmaceutical
Regions
North America

United States

Subjects
Legislation

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical United States Legislation

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS055516

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS055516

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Biosimilars Wedge Issue: Actavis Splits With GPhA In Supporting Calif. Notification Bill

News

Executive Summary

Related Content

Amgen, Watson Aim To Launch First Joint Oncology Biosimilar In U.S. In 2017

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert